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BSTRACT
 
Background
 
The global initiative to eradicate ban-
croftian filariasis currently relies on mass treatment
with four to six annual doses of antifilarial drugs. The
goal is to reduce the reservoir of microfilariae in the
blood to a level that is insufficient to maintain trans-
mission by the mosquito vector.
 
Methods
 
In  nearly  2500  residents  of  Papua  New
Guinea, we prospectively assessed the effects of four
annual treatments with a single dose of diethylcar-
bamazine plus ivermectin or diethylcarbamazine alone
on the incidence of microfilariae-positive infections,
the severity of lymphatic disease, and the rate of trans-
mission of 
 
Wuchereria bancrofti
 
 by mosquitoes. Ran-
dom assignment to treatment regimens was carried
out according to the village of residence, and villages
were categorized as having moderate or high rates of
transmission.
 
Results
 
The four annual treatments with either drug
regimen were taken by 77 to 86 percent of the mem-
bers of the population who were at least five years old;
treatments were well tolerated. The proportion with
microfilariae-positive infections decreased by 86 to 98
percent, with a greater reduction in areas with a mod-
erate rate of transmission than in those with a high
rate. The respective aggregate frequencies of hydro-
cele and leg lymphedema were 15 percent and 5 per-
cent before the trial began, and 5 percent (P<0.001)
and 4 percent (P=0.04) after five years. Hydrocele and
leg lymphedema were eliminated in 87 percent and
69 percent, respectively, of those who had these con-
ditions  at  the  outset.  The  rate  of  transmission  by
mosquitoes decreased substantially, and new microfi-
lariae-positive infections in children were almost com-
pletely prevented over the five-year study period.
 
Conclusions
 
Annual  mass  treatment  with  drugs
such as diethylcarbamazine can virtually eliminate the
reservoir of microfilariae and greatly reduce the fre-
quency of clinical lymphatic abnormalities due to ban-
croftian filariasis. Eradication may be possible in areas
with moderate rates of transmission, but longer pe-
riods of treatment or additional control measures may
be necessary in areas with high rates of transmission.
(N Engl J Med 2002;347:1841-8.)
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ANCROFTIAN filariasis causes elephantiasis,
hydrocele, and economic loss throughout the
tropics and subtropics. A global plan for its
eradication is based on the notion that mass
treatment with antifilarial drugs will reduce the res-
ervoir of microfilariae in the blood to a level that is
insufficient to sustain transmission by the mosquito
vector.
 
1-3
 
 The feasibility of the strategy is supported
by observations that drugs given only once per year
(diethylcarbamazine alone, diethylcarbamazine plus
ivermectin, albendazole plus ivermectin, or albenda-
zole plus diethylcarbamazine) decrease the reservoir
of microfilariae.
 
4-6
 
 The threshold below which trans-
mission will be interrupted is not known, but math-
ematical models that assume the reproductive life span
of 
 
Wuchereria bancrofti
 
 is approximately five years pre-
dict that annual mass treatment for four to six years
will be required.
 
7,8
 
In 1994 we initiated a trial comparing the efficacy
of diethylcarbamazine plus ivermectin with that of di-
ethylcarbamazine alone in limiting the transmission of
filariasis in Papua New Guinea. The proportion of per-
sons who were positive for microfilariae decreased by
76 to 99 percent, and the transmission potential —
the estimated number of infective (third-stage) larvae
inoculated per person per year — decreased by 31 to
58 percent 12 months after a single dose of the drugs.
 
9
 
In the current study, we assessed the influence of base-
line transmission levels and the effect of four annual
antifilarial treatments on three key end points of fil-
ariasis control: the reservoir of microfilariae, the sever-
ity of lymphatic abnormalities, and the incidence of
new infections.
 
METHODS
 
Study Population and Randomization
 
Residents of 14 villages (hereafter referred to as units or treatment
units) in the Dreikikir district of Papua New Guinea participated in
this open-label study comparing the efficacy of a single annual dose
of diethylcarbamazine plus ivermectin (6 mg per kilogram of body
B
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weight and 400 µg per kilogram, respectively) with that of a sin-
gle annual dose of diethylcarbamazine alone (6 mg per kilogram)
in reducing the transmission of 
 
W. bancrofti.
 
 The method of ran-
domization and the categorization of 8 treatment units as having
a moderate rate of transmission and of 6 as having a high rate of
transmission have been described previously.
 
9-12
 
The procedure for oral informed consent and the study design
were approved by the Medical Research Advisory Committee of
Papua New Guinea and the institutional review board for human
investigations at Case Western Reserve University in Cleveland.
Consent for the participation of subjects who were 16 years old or
younger was obtained from a parent or guardian. Only persons who
were at least five years old were eligible to receive drugs. Children
who reached their fifth birthday within the 12-month period pre-
ceding an annual treatment were given their first treatment at that
time. Pregnant women were excluded from receiving the drugs, be-
cause ivermectin cannot be used during pregnancy.
 
Drug Distribution and Adverse Effects
 
Diethylcarbamazine (50-mg tablets) and ivermectin (1-mg tab-
lets) were supplied by the World Health Organization. Because re-
actions to antifilarial drugs are most severe in persons with high
levels of microfilariae,
 
13,14
 
 we closely monitored 966 subjects for side
effects after the first treatment. Minor reactions (myalgia, headache,
fatigue, and swelling of an arm, a leg, or genitalia) and severe reac-
tions (high fever, shortness of breath, and collapse) that occurred
within 48 hours after drug administration were recorded. Acetamin-
ophen was given for minor reactions.
 
Measures of Infection and Disease
 
Infection status was evaluated one day before the first treatment
in 1994 and yearly after the first, second, third, and fourth annual
treatments. The density of microfilariae in 1 ml of blood and the
Og4C3 antigen level were quantified by membrane filtration and
enzyme-linked immunosorbent assay (TropBioMed), respective-
ly.
 
15,16
 
 The proportion of subjects who were positive for microfi-
lariae and the geometric mean number of microfilariae per milliliter
of blood before and one year after each treatment were calculated.
Physical examination was performed annually, and the severity of
lymphatic abnormalities was graded according to standard criteria.
 
17
 
Only subjects who were at risk for advanced hydrocele (male sub-
jects who were at least 16 years old) and moderate-to-severe lymph-
edema of the legs (subjects who were at least 21 years old) were
scored as positive for disease. An adult with lymphedema of the legs
and arms is shown in Figure 1.
 
Entomologic Studies
 
Mosquitoes were captured for four nights per month as they
landed on the legs of adult residents of the study area. The mosqui-
to species was determined, and insects were examined for infective
(third-stage) larvae.
 
18,19
 
 The biting rate (the number of mosquitoes
attempting to take a blood meal per person), the infective biting
rate (the number of 
 
Anopheles punctulatus
 
 that had at least one in-
fective larva), and the transmission potential were determined.
 
20,21
 
Statistical Analysis
 
The frequency of adverse reactions according to the treatment
regimen, differences in the proportion of subjects who were positive
for microfilariae before and after each treatment, and changes in the
antigen level and the severity of lymphatic abnormalities were eval-
uated for significance with the use of chi-square tests. Differences in
the rates of transmission before and after treatment were evaluated
with use of the Mann–Whitney U test. A generalized estimating
equation was used to assess the difference in the odds of having a
microfilariae-positive infection according to the treatment regimen
and rate of transmission (moderate or high) after adjustment for the
correlation of observations within treatment units over time.
 
22
 
 The
logarithmic odds of lymphedema of the legs and hydrocele were
modeled with use of the same technique. The resulting estimates
were converted to odds ratios with 95 percent confidence intervals
calculated from the robust estimator of variance. Modeling was
performed with SAS 8.2 software (SAS Institute) with use of the
GENMOD procedure.
 
RESULTS
 
Community Participation in Mass Treatment
 
A total of 2586 persons were eligible to take antifi-
larial drugs in 1994, 2668 were eligible in 1995, 2695
were eligible in 1996, and 2690 were eligible in 1997.
Ineligible persons (14 percent of the de facto popu-
lation) were primarily children younger than five years
old. Eighty-six percent of eligible subjects took antifi-
larial drugs during the first annual treatment, 78 per-
cent during the second, 80 percent during the third,
and 77 percent during the fourth. Of the 2586 sub-
jects enrolled in 1994, 1 percent received no doses of
 
Figure 1.
 
 A 52-Year-Old Papua New Guinea Man with Elephan-
tiasis of the Legs and Lymphedema of the Arms.
This man also had an advanced hydrocele.
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antifilarial drugs, 19 percent received one dose, 21 per-
cent received two doses, 24 percent received three
doses, and 35 percent received all four doses. Fifty per-
cent of the episodes of noncompliance were not ran-
dom (e.g., half the subjects who did not take the med-
ication in 1997 also did not do so in 1995 and 1996).
There were no significant differences between the
number of doses of diethylcarbamazine plus ivermec-
tin that were taken and the number of doses of diethyl-
carbamazine alone that were taken.
 
Adverse Reactions
 
No severe reactions were observed. Minor reactions
were reported after the first treatment by 20 percent
of subjects who took diethylcarbamazine plus ivermec-
tin (93 of 472) and 11 percent of subjects who took
diethylcarbamazine alone (53 of 494) (
 
x
 
2
 
=14.3, P<
0.01). Seven hundred fifty-four of these subjects took
the medications the following year. Nine of 146 sub-
jects who had minor side effects after the first treat-
ment (6 percent) declined to take the second annual
dose, as compared with 111 of 608 who did not have
an adverse reaction after the first treatment (18 per-
cent) (
 
x
 
2
 
=11.9, P<0.01).
 
Effect of Treatment on the Reservoir of Microfilariae
 
Annual treatment reduced the reservoir of microfi-
lariae (Table 1). The initial decrease was greatest in
treatment units with a moderate rate of transmission
whose inhabitants were randomly assigned to receive
diethylcarbamazine plus ivermectin. Forty-seven per-
cent of such subjects were positive for microfilariae
before the initial treatment, as compared with 1 per-
cent one year after the fourth treatment (
 
x
 
2
 
=475.9,
P<0.001). In units with a high rate of transmission,
the rate of positivity for microfilariae decreased from
77 percent to 5 percent during the same period (
 
x
 
2
 
=
287.5, P<0.001). In units whose inhabitants were ran-
domly assigned to receive diethylcarbamazine alone,
the rates decreased from 42 percent before the initial
treatment to 2 percent one year after the fourth treat-
ment in areas with a moderate rate of transmission and
from 76 percent to 11 percent in areas with a high rate
of transmission.
A generalized estimating equation was used to ac-
count for the correlation of observations clustered
within various treatment units. The model to estimate
the odds of microfilarial infection included the drug
regimen, the estimated transmission potential before
treatment, the year of observation, and an interaction
term for year and treatment regimen that was based on
a logit link and an independent working correlation
structure. The efficacy of diethylcarbamazine plus iver-
mectin was greater than that of diethylcarbamazine
alone one year after the first, second, and third annual
treatments (Fig. 2). For example, after the third treat-
ment, residents of sites randomly assigned to receive
diethylcarbamazine alone were 3.3 times as likely to
be positive for microfilariae as those who lived in areas
where diethylcarbamazine plus ivermectin was given
(95 percent confidence interval, 1.04 to 10.57; P=
0.04), and the odds of being positive for microfilar-
iae were 3.5 times as great for residents of areas with
a high rate of transmission as for residents of areas
 
*Four treatment units with a moderate transmission rate were randomly assigned to receive diethylcarbamazine plus ivermectin, and four were assigned
to receive diethylcarbamazine alone; three treatment units with a high transmission rate were randomly assigned to receive diethylcarbamazine plus iver-
mectin, and three were assigned to receive diethylcarbamazine alone.
†P<0.001 for the comparison with all other years.
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1994 1995 1996 1997 1998 1994 1995 1996 1997 1998
 
Diethylcarbamazine plus 
ivermectin
 
No. of subjects examined 797 756 790 819 750 281 318 311 303 266
No. of microfilariae-positive 
subjects (%)
376 (47)† 156 (21) 45 (6) 8 (1) 7 (1) 216 (77)† 101 (32) 74 (24) 33 (11) 14 (5)
Geometric mean no. of
microfilariae/ml
9.6 0.9 0.3 0.3 0.5 49.8 2.9 2.6 0.6 0.3
 
Diethylcarbamazine alone
 
No. of subjects examined 903 815 802 692 639 243 192 253 257 165
No. of microfilariae-positive 
subjects (%)
381 (42)† 238 (29) 121 (15) 47 (7) 10 (2) 185 (76)† 98 (51) 107 (42) 56 (22) 18 (11)
Geometric mean no. of
microfilariae/ml
8.8 2.6 0.9 0.3 0.5 55.2 13.1 7.8 1.4 0.5
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with a moderate rate of transmission (95 percent con-
fidence interval, 1.30 to 9.09; P=0.02). After the
fourth treatment, however, the odds of microfilariae-
positive infection decreased to less than 0.1, regard-
less of whether subjects lived in an area with a mod-
erate or a high rate of transmission and regardless of
whether they were given diethylcarbamazine plus iver-
mectin or diethylcarbamazine alone.
 
Effect of Treatment on Transmission
 
Before treatment, there were 24 to 167 bites from
mosquitoes containing infective larvae per person per
year in treatment units with a moderate rate of trans-
mission and 224 to 742 infective bites per person per
year in units with a high rate of transmission; the re-
spective ranges for the transmission potential were 45
to 404 and 704 to 2518 infective larvae inoculated
per person per year. Detailed entomologic indexes in
two treatment units where diethylcarbamazine plus
ivermectin was used are presented in Figure 3.
In the unit with a moderate rate of transmission, the
overall transmission potential decreased by 97 percent
(from 704 to 23 infective larvae inoculated per per-
son per year). The effect of treatment was less marked
in the unit with a higher rate of transmission. The pre-
treatment transmission potential of 1485 infective lar-
vae inoculated per person per year decreased to 234
infective larvae inoculated per person per year the year
after the third annual treatment (84 percent reduc-
tion). The pattern of exposure to infective mosqui-
toes also differed according to the pretreatment rate
of transmission. In units with a moderate rate of trans-
mission before treatment, after treatment there was
an average of 0 bites from infective mosquitoes per
person per month during 11 months of the year. In
contrast, in units with a high rate of transmission be-
fore treatment, rates remained moderate to high (1 to
more than 30 bites from infective mosquitoes per per-
son per year) for five to seven months per year after
treatment was initiated.
To estimate the effect of mass treatment on the es-
tablishment of new infections, we compared the prev-
alence of microfilariae-positive infections in previously
untreated cohorts of five-to-six-year-old children from
each year of the study for the treatment regimens com-
bined. Before the initial treatment, 28 of 64 children
(44 percent) were positive for microfilariae. A total of
9 percent were positive for microfilariae in 1995 (3 of
32), 11 percent in 1996 (8 of 71), 2 percent in 1997
(1 of 42), and 6 percent in 1998 (3 of 52) (
 
x
 
2
 
=12.9
for the comparison between the pretreatment value
and the value in 1998, P<0.001).
 
Effect on Filarial Antigen Level
 
Estimates of the levels of circulating filarial antigen
alone, independent of the blood level of microfilari-
ae, are thought to reflect the burden of pre-adult and
adult worms.
 
23-25
 
 Antigen levels were monitored be-
tween 1994 and 1997 in residents of two treatment
units (Table 2). Fewer than 20 percent of subjects who
were antigen-positive before the trial began were an-
tigen-negative one year after the third annual treat-
ment, though mean antigen levels decreased by 79
percent. There was no significant difference in these
proportions between the two drug regimens. Chang-
es in antigen status and level did not correlate with the
number of treatments a subject received. No subjects
who were identified as antigen-negative before the
trial began were antigen-positive in subsequent years,
and in no case did the antigen level increase relative
to the pretreatment value.
 
Effect of Treatment on Hydrocele and Leg Lymphedema
 
The proportion of male subjects with advanced hy-
drocele who were at least 16 years old was 15 percent
(110 of 726) before the trial began and 5 percent (27
of 563) one year after the fourth treatment (x2=35.8,
P<0.001). There was no significant difference in the
frequency or odds of hydrocele between the two drug
regimens, after adjustment for the clustering of treat-
Figure 2. Odds of Microfilariae-Positive Infection over the Five-
Year Study Period among Subjects in Treatment Areas with Mod-
erate and High Rates of Transmission Randomly Assigned to
Receive Diethylcarbamazine plus Ivermectin or Diethylcarbam-
azine Alone.
The first annual dose of each drug regimen was given immedi-
ately after the determination of microfilarial status in 1994. The
odds of microfilariae-positive infection were less than 0.1 in 1998,
regardless of the drug regimen or the base-line transmission
potential.
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ment units and time, although the odds did decrease
with each year (P=0.02). In addition, the odds of hy-
drocele were 2.4 times as great among residents of
areas with a high rate of transmission as among res-
idents of areas with a moderate rate of transmission
over the four-year period of the study (95 percent
confidence interval, 2.05 to 4.76; P=0.02).
The frequency of lymphedema of the legs was 5 per-
cent before treatment (68 of 1273 subjects) and 4 per-
cent after the fourth treatment (35 of 998 subjects;
x2=4.4; P=0.04). There was no significant differ-
ence between the two drug regimens in the odds of
lymphedema of the legs, although the odds decreased
each year (P=0.03). Residents of units with a high
rate of transmission were 3.3 times as likely to have
lymphedema as residents of units with a moderate rate
of transmission over the four-year study period (95
percent confidence interval, 1.33 to 8.33; P=0.01).
A separate analysis was performed that included
subjects who had lymphatic disease at the beginning
of the trial and who were monitored during the five-
year study period. Ninety-one of 105 men who had
advanced hydrocele (87 percent) and 62 of 90 adults
who had lymphedema of the legs (69 percent) in 1993
to 1994 no longer had clinical signs of disease in 1998.
The likelihood of the amelioration of lymphatic ab-
normalities did not correlate with the drug regimen,
the number of treatments actually received, or the
change in infection status as judged by the number of
microfilariae or the antigen level.
DISCUSSION
In an effort to eradicate bancroftian filariasis, mass
treatment with four to six annual doses of antifilarial
drugs  is  being  implemented  in  some  parts  of  the
world.26,27 Our findings support this strategy for areas
with low-to-moderate rates of transmission in regions
where anopheline mosquitoes transmit this infectious
disease, such as in Melanesia and Africa. Additional
measures or longer periods of treatment may be nec-
Figure 3. Entomologic Indexes of Transmission in Two Units with Differing Rates of Transmission Randomly Assigned to Receive
Diethylcarbamazine plus Ivermectin.
The biting rate (the estimated number of mosquitoes attempting to take a blood meal per person per year), infective biting rate (the
estimated number of bites from mosquitoes containing infective larvae per person per year), and the transmission potential (the es-
timated number of infective larvae inoculated per person per year) are shown. In each horizontal bar, the sections represent the 12
months of the year.
Transmission rate, 704 infective larvae/person/yr
Mosquito
Bites
Bites from
Mosquitoes
Containing
Infective
Larvae
Infective
Larvae
Inoculated
estimated no./person/yr
No.  of Bites from Infective Mosquitoes/Person/Month
1993–1994 (pretreatment)
1994–1995 9,102
8,194
9,378
8,915
8
224
8
8
8
704
23
8 1995–1996
1996–1997
Transmission rate, 1485 infective larvae/person/yr
1993–1994 (pretreatment)
1994–1995 18,026
42,328
23,438
17,701
85
565
77
93
231
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1996–1997
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essary in areas with a high rate of transmission. Since
the efficiency of transmission varies among mosquito
species, it is not yet clear whether similar conclusions
can be drawn in areas where non-anopheline mos-
quitoes transmit W. bancrofti.
Our results suggest that mass treatment will be well
accepted. Serious adverse reactions were not observed
after 8335 doses of diethylcarbamazine plus ivermec-
tin or diethylcarbamazine alone had been given, and
77 to 86 percent of eligible subjects received at least
one of the four annual treatments. Although minor
side effects such as myalgia and fatigue were noted by
one sixth of subjects after the first treatment, such re-
actions were associated with increased rates of partic-
ipation the following year, possibly because adverse ef-
fects were perceived as indicators of the efficacy of the
treatment. Acute post-treatment reactions may be me-
diated by inflammatory cytokines that are up-regulat-
ed when filarial antigens and wolbachia-derived mol-
ecules are released by dying microfilariae.28,29
Mass treatment reduced the burden of clinical lym-
phatic disease. The prevalence of hydrocele decreased
from 15 percent to 5 percent, and scrotal swelling
disappeared in 87 percent of male subjects with pre-
existing genital disease. Similarly, the prevalence of
lymphedema of the legs decreased from 5 percent to
4 percent, and 69 percent of subjects with preexist-
ing disease had a clinical cure. Reports from other ar-
eas in which bancroftian filariasis is endemic suggest
that the beneficial effects we observed may be gener-
alizable.30,31 The mechanism by which overt lymphatic
disease is reversed is not known, but the infection does
not need to be cured, since filarial antigenemia per-
sisted in most subjects and there was no correlation
between this finding and the number of treatments
actually received. We speculate that mass treatment de-
creases exposure to the infective larvae and that this,
in turn, diminishes the intensity of inflammatory re-
sponses to newly inoculated W. bancrofti or their wol-
bachia endosymbionts. Studies have shown that the
rate of transmission correlates with both the prevalence
of lymphatic abnormalities and the cytokine profile
and strength of filarial-specific T-cell immunity.32,33
Four annual treatments reduced the proportion of
subjects who were positive for microfilariae by 86 to
98 percent and the geometric mean density of mi-
crofilariae to less than 1 in all groups. Decreases in the
reservoir of microfilariae were more pronounced after
treatment with diethylcarbamazine plus ivermectin
than after treatment with diethylcarbamazine alone,
and the reduction in the microfilariae-positive rates was
initially greater in areas with a moderate rate of trans-
mission than in areas with a high rate of transmission.
After the fourth treatment, however, the odds of being
positive for microfilariae were similar in all groups
regardless of the rate of transmission or the drug reg-
imen. It is important to consider these results in the
context of the high rates of transmission and infection
in Papua New Guinea relative to other areas of en-
demic infection. Microfilariae-positive rates of 20 to
30 percent and transmission potentials of approximate-
ly 400 infective larvae per person per year (defined as
*Subjects were treated in 1994, 1995, and 1996. Plasma Og4C3 antigen levels were determined
by two-site enzyme-linked immunosorbent assay.
†Ninety subjects in this treatment unit were evaluated for Og4C3 antigen in 1994; 10 were neg-
ative. None were antigen-positive in 1997.
‡Sixty-five subjects in this treatment unit were evaluated for Og4C3 antigen in 1994; 11 were neg-
ative. None were antigen-positive in 1997.
TABLE 2. FILARIAL ANTIGEN LEVELS BEFORE AND AFTER THREE ANNUAL CYCLES
OF MASS TREATMENT WITH DIETHYLCARBAMAZINE PLUS IVERMECTIN
OR DIETHYLCARBAMAZINE ALONE IN TWO TREATMENT UNITS.*
TREATMENT
NO. OF 
SUBJECTS
NO. OF
ANTIGEN-POSITIVE
SUBJECTS
PERCENT
CONVERTING FROM
POSITIVE TO NEGATIVE
MEAN
DECREASE IN
ANTIGEN LEVEL
1994 1997
%
Diethylcarbamazine
plus ivermectin
1 Dose
2 Doses
3 Doses
80†
16
31
33
16
28
32
0
10
3
86
86
76
Diethylcarbamazine alone
1 Dose
2 Doses
3 Doses
54‡
5
12
37
5
10
34
0
17
8
80
89
82
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a moderate rate in our study) are considered high in
most regions of Africa and the Pacific islands.10,11,34-36
In addition, recommendations to include albendazole
in mass-treatment programs will most likely lead to
even greater efficacy, since this drug, like diethylcar-
bamazine, is active against adult worms.
The remarkable decreases in the reservoir of microfi-
lariae and the rates of transmission were accompanied
by an 87 percent reduction from the pretreatment val-
ue in the number of microfilariae-positive infections in
previously untreated five-to-six-year-old children after
the fourth annual treatment. Since the children who
were evaluated after the fourth treatment were 1 to
12 months old during the pretreatment period, the
few infections in this group are most likely due to ex-
posure to infective larvae before the transmission rate
had been diminished by mass treatment. If this ex-
planation is correct, the data indicate that new infec-
tions  were  completely  prevented  after  four  annual
treatments.
Observations from other areas in which filariasis is
endemic suggest that intense courses of diethylcar-
bamazine given over a period of 10 or more years in-
terrupt transmission,37-42 whereas a recent report from
India, where culicine mosquitoes transmit W. bancrof-
ti, shows that the rates of microfilariae-positive infec-
tion decreased by 48 percent after four annual treat-
ments with diethylcarbamazine alone.43 Comparison
of these reports with our data is difficult, since none
included a prospective analysis of the transmission po-
tential, the levels of microfilariae or filarial antigen,
the rate of new infections, or the influence of the base-
line transmission rate.
Our results support the concept that infection and
the burden of disease due to bancroftian filariasis can
be reduced substantially with as few as four annual
mass treatments that include single doses of diethyl-
carbamazine. It is not yet known whether and how
long these benefits will be sustained after mass treat-
ment ceases. Eradication may ultimately require more
than four to six years of treatment, drugs with greater
activity against adult worms, or adjunctive strategies
that limit exposure to mosquitoes or enhance resist-
ance to infection. Evaluation of changes in filarial ecol-
ogy after the cessation of mass treatment in Papua
New Guinea and other areas of endemic infection will
provide this information and can be used to validate
and refine mathematical models designed to predict
the threshold necessary to achieve eradication.7,8,44,45
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